Pulmonary

Clindamycin injection is used to treat certain types of bacterial infections, including infections of the lungs, skin, blood, bones, joints, female reproductive organs, as well as internal organs.

Indication: As an aid in the treatment of respiratory tract conditions such as cough, phlegm, the common cold, and smoker's cough.

Instructions for use: CHILDREN: 1/2 cup (10 ml) every 4 hours. ADULTS: 1 cup (20 ml) every 4 hours Function: AIDS WITH RESPIRATORY TRACT DISCOMFORT Ingredients: Eucalyptus and Mullein: Expectorant, primarily used for respiratory illnesses. Elderberry: Stimulates and strengthens the immune system, cures respiratory illnesses and fevers. Myrrh: Used to reduce throat inflammation. Biofarma Laboratory

It is used in the treatment of bronchial asthma, reversible bronchospasm and other processes associated with reversible airway obstruction. Mechanism of action Salbutamol A selective ß2-adrenergic agonist of bronchial smooth muscle, it provides short-term bronchodilation in reversible airway obstruction. With little or no action on ß1-adrenergic receptors of the heart muscle.

Therapeutic Indications Clarithromycin - Oral, in normal-release and modified-release forms: Adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in normal-release forms: Adults and children ≥12 years: localized or disseminated M. avium or M. intracellulare infection, localized M. chelonae, M. fortuitum, and M. kansaii infection, gastric or duodenal ulcer associated with H. pylori (with an appropriate antiulcer agent). Prevention of disseminated M. avium complex infection in high-risk HIV patients (CD4 lymphocytes ≤ 50/mm 3 ). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adv.: Parenteral treatment for streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated sensitivity to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-moderate skin and soft tissue infections if beta-lactams are not appropriate. It is a macrolide antibiotic with bactericidal action and is effective against a wide range of aerobic and anaerobic bacteria, as well as gram-positive and gram-negative bacteria. It is used for upper and lower respiratory tract infections, skin and soft tissue infections, and infections caused by the Mycobacterium complex (M.

AMIKACIN-AMSA INJECTION 500 Amikacin injection belongs to a class of medications called aminoglycoside antibiotics. It works by eliminating bacteria. Antibiotics such as amikacin injection do not work against colds, influenza, or any other viral infection. C/1 Therapeutic Indications Amikacin Short-term treatment of serious infections caused by gram-sensitive microorganisms: Pseudomonas, E. coli, Proteus (indole-positive and indole-negative), Providencia, Klebsiella, Enterobacter, Serratia, and Acinetobacter (Mima-Herellea). Short-term treatment of serious infections caused by susceptible strains of microorganisms such as: septicemia (including neonatal sepsis); severe respiratory tract infections; CNS infections (meningitis); intra-abdominal infections (including peritonitis); complicated and recurrent urinary tract infections, where treatment is not possible with other less toxic antibiotics; Skin, bone, soft tissue, and joint infections; burn infections; postoperative infections (including post-vascular surgery).

Therapeutic Indications Cefaclor Otitis media due to: S. pneumoniae, H. influenzae, staphylococci, S. pyogenes, and M. catarrhalis; lower respiratory tract infection, pneumonia due to: S. pneumoniae, H. influenzae, S. pyogenes, and M. catarrhalis; upper respiratory tract infection, pharyngitis and tonsillitis due to: S. pyogenes and M. catarrhalis; urinary tract infection, cystitis and pyelonephritis due to: E. coli, P. mirabilis, Klebsiella, and coagulase-causing staphylococci; skin and soft tissue infection due to: S. aureus and S. pyogenes. Sinusitis. Gonococcal urethritis. Laboratorios Maver

Useful in the treatment of respiratory tract infections, bacterial sinusitis, otitis media, skin and soft tissue infections, bone and joint infections, genitourinary tract infections, including acute prostatitis, and dental infections.

Clarithromycin is useful for the treatment of: Upper respiratory tract infections (tonsillitis, pharyngitis, sinusitis, otitis). Lower respiratory tract infections (bronchitis, pneumonia). Therapeutic indications for Clarithromycin: - Oral, in immediate-release and modified-release formulations: Adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in immediate-release formulations: Adults and children ≥12 years: localized or disseminated infection caused by M. avium or M. intracellulare, localized infection caused by M. chelonae, M. fortuitum, and M. kansaii. Gastric or duodenal ulcer associated with H. pylori (in conjunction with appropriate anti-ulcer medication). Prevention of disseminated M. avium complex infection in high-risk HIV patients (CD4 lymphocytes ≤ 50/mm³). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adults: parenteral treatment of streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated susceptibility to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-to-moderate skin and soft tissue infections if beta-lactams are not appropriate.

Therapeutic Indications Clarithromycin - Oral, in immediate-release and modified-release formulations: adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in immediate-release formulations: adults and children ≥12 years: localized or disseminated infection caused by M. avium or M. intracellulare, localized infection caused by M. chelonae, M. fortuitum, and M. kansaii. Gastric or duodenal ulcer associated with H. pylori (in conjunction with an appropriate anti-ulcer agent). Prevention of disseminated M. avium complex infection in high-risk HIV-positive patients (CD4 lymphocytes ≤ 50/mm³). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adults: parenteral treatment of streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated susceptibility to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-to-moderate skin and soft tissue infections if beta-lactams are not appropriate.

Dexamethasone 8 mg/ml injectable solution: Treatment of cerebral edema secondary to brain tumors, head trauma, neurosurgery, brain abscesses, or bacterial meningitis. Treatment of traumatic shock. Treatment of severe acute asthma or status asthmaticus. Initial parenteral treatment of severe acute extensive dermatological diseases such as erythroderma, pemphigus vulgaris, or acute eczema. Initial parenteral treatment of active phases of collagenoses such as systemic lupus erythematosus, especially visceral forms. Treatment of severe infectious diseases (e.g., typhoid fever, brucellosis, tuberculosis), only as adjunctive therapy to appropriate anti-infective therapy. Prophylaxis and treatment of nausea and vomiting induced by cytostatics and after surgical interventions within the context of antiemetic regimens. Short-term adjunctive treatment during acute episodes or exacerbations of rheumatic diseases. Dexamethasone 40 mg/5 ml injectable solution: Treatment of cerebral edema secondary to brain tumors and head trauma. Treatment of traumatic shock. Treatment of anaphylactic shock (as post-primary epinephrine injection therapy).

ENT, respiratory, dental, gastrointestinal, genitourinary, skin and soft tissue, neurological, surgical, trauma, bacterial meningitis and sepsis infections.